 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- || zansecimab (LY3127804) / Eli Lilly
Clinical, Journal: Efficacy and Safety of LY3127804, an Anti-Angiopoietin-2 Antibody, in a Randomized, Double-Blind, Placebo-Controlled Clinical Trial in Patients Hospitalized with Pneumonia and Presumed or Confirmed COVID-19. (Pubmed Central) - Aug 24, 2022
P2
LY3127804 treatment did not decrease the need for ventilator usage in patients hospitalized with pneumonia and presumed or confirmed COVID-19.
- || Cyramza (ramucirumab) / Eli Lilly, zansecimab (LY3127804) / Eli Lilly
Clinical, P1 data, Journal, Combination therapy, Monotherapy: First-in-human, dose-escalation, phase 1 study of anti-angiopoietin-2 LY3127804 as monotherapy and in combination with ramucirumab in patients with advanced solid tumours. (Pubmed Central) - Mar 24, 2021
LY3127804 monotherapy and its combination with ramucirumab are well tolerated. LY3127804 20 mg/kg was the recommended Phase 2 dose.
- | zansecimab (LY3127804) / Eli Lilly
Enrollment change, Trial termination: A Study of LY3127804 in Participants With COVID-19 (clinicaltrials.gov) - Oct 28, 2020
P2, N=95, Terminated, Sponsor: Eli Lilly and Company
LY3127804 20 mg/kg was the recommended Phase 2 dose. N=210 --> 95 | Active, not recruiting --> Terminated; Trial terminated for futility.
- ||| Cyramza (ramucirumab) / Eli Lilly, zansecimab (LY3127804) / Eli Lilly
Trial completion, Trial completion date, Combination therapy, Monotherapy, Metastases: A Study of LY3127804 With Ramucirumab in Participants With Advanced Solid Tumors (clinicaltrials.gov) - Oct 19, 2020
P1, N=105, Completed, Sponsor: Eli Lilly and Company
N=210 --> 95 | Active, not recruiting --> Terminated; Trial terminated for futility. Trial completion date: Nov 2020 --> May 2020 | Active, not recruiting --> Completed
- ||| zansecimab (LY3127804) / Eli Lilly
Enrollment closed: A Study of LY3127804 in Participants With COVID-19 (clinicaltrials.gov) - Aug 20, 2020
P2, N=210, Active, not recruiting, Sponsor: Eli Lilly and Company
Trial completion date: Nov 2020 --> May 2020 | Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- || zansecimab (LY3127804) / Eli Lilly
Trial primary completion date: A Study of LY3127804 in Participants With COVID-19 (clinicaltrials.gov) - Jun 15, 2020
P2, N=200, Recruiting, Sponsor: Eli Lilly and Company
Recruiting --> Active, not recruiting Trial primary completion date: Jun 2020 --> Sep 2020
- | Cyramza (ramucirumab) / Eli Lilly, zansecimab (LY3127804) / Eli Lilly
Trial completion date, Combination therapy, Monotherapy, Metastases: A Study of LY3127804 With Ramucirumab in Participants With Advanced Solid Tumors (clinicaltrials.gov) - May 5, 2020
P1, N=105, Active, not recruiting, Sponsor: Eli Lilly and Company
Trial primary completion date: Jun 2020 --> Sep 2020 Trial completion date: May 2020 --> Nov 2020
- ||| zansecimab (LY3127804) / Eli Lilly
Enrollment open: A Study of LY3127804 in Participants With COVID-19 (clinicaltrials.gov) - Apr 21, 2020
P2, N=200, Recruiting, Sponsor: Eli Lilly and Company
Trial completion date: May 2020 --> Nov 2020 Not yet recruiting --> Recruiting
- |||| zansecimab (LY3127804) / Eli Lilly
New P2 trial: A Study of LY3127804 in Participants With COVID-19 (clinicaltrials.gov) - Apr 12, 2020
P2, N=200, Not yet recruiting, Sponsor: Eli Lilly and Company
- | Cyramza (ramucirumab) / Eli Lilly, zansecimab (LY3127804) / Eli Lilly
Trial completion date, Combination therapy, Monotherapy, Metastases: A Study of LY3127804 With Ramucirumab in Participants With Advanced Solid Tumors (clinicaltrials.gov) - Nov 19, 2019
P1, N=105, Active, not recruiting, Sponsor: Eli Lilly and Company
Not yet recruiting --> Recruiting Trial completion date: Nov 2019 --> May 2020
- | Cyramza (ramucirumab) / Eli Lilly, zansecimab (LY3127804) / Eli Lilly
Trial completion date, Combination therapy, Monotherapy, Metastases: A Study of LY3127804 With Ramucirumab in Participants With Advanced Solid Tumors (clinicaltrials.gov) - Jun 18, 2019
P1, N=105, Active, not recruiting, Sponsor: Eli Lilly and Company
Trial completion date: Nov 2019 --> May 2020 Trial completion date: Jun 2019 --> Nov 2019
- | Cyramza (ramucirumab) / Eli Lilly, zansecimab (LY3127804) / Eli Lilly
Trial completion date, Combination therapy, Monotherapy, Metastases: A Study of LY3127804 With Ramucirumab in Participants With Advanced Solid Tumors (clinicaltrials.gov) - Feb 16, 2019
P1, N=105, Active, not recruiting, Sponsor: Eli Lilly and Company
Trial completion date: Jun 2019 --> Nov 2019 Trial completion date: Feb 2019 --> Jun 2019
- | Cyramza (ramucirumab) / Eli Lilly, zansecimab (LY3127804) / Eli Lilly
Trial completion date, Combination therapy, Monotherapy, Metastases: A Study of LY3127804 With Ramucirumab in Participants With Advanced Solid Tumors (clinicaltrials.gov) - Nov 21, 2018
P1, N=105, Active, not recruiting, Sponsor: Eli Lilly and Company
Trial completion date: Feb 2019 --> Jun 2019 Trial completion date: Nov 2018 --> Feb 2019
- | Cyramza (ramucirumab) / Eli Lilly, zansecimab (LY3127804) / Eli Lilly
Trial completion date, Combination therapy, Monotherapy, Metastases: A Study of LY3127804 With Ramucirumab in Participants With Advanced Solid Tumors (clinicaltrials.gov) - Sep 17, 2018
P1, N=105, Active, not recruiting, Sponsor: Eli Lilly and Company
Trial completion date: Nov 2018 --> Feb 2019 Trial completion date: Aug 2018 --> Nov 2018
- || Cyramza (ramucirumab) / Eli Lilly, zansecimab (LY3127804) / Eli Lilly
Enrollment closed, Trial completion date, Combination therapy, Monotherapy, Metastases: A Study of LY3127804 With Ramucirumab in Participants With Advanced Solid Tumors (clinicaltrials.gov) - Mar 30, 2018
P1, N=105, Active, not recruiting, Sponsor: Eli Lilly and Company
Trial completion date: Aug 2018 --> Nov 2018 Completed --> Active, not recruiting | Trial completion date: Nov 2017 --> Aug 2018
- ||| Cyramza (ramucirumab) / Eli Lilly, zansecimab (LY3127804) / Eli Lilly
Trial completion, Combination therapy, Monotherapy, Metastases: A Study of LY3127804 With Ramucirumab in Participants With Advanced Solid Tumors (clinicaltrials.gov) - Dec 6, 2017
P1, N=105, Completed, Sponsor: Eli Lilly and Company
Completed --> Active, not recruiting | Trial completion date: Nov 2017 --> Aug 2018 Active, not recruiting --> Completed
- || Cyramza (ramucirumab) / Eli Lilly, zansecimab (LY3127804) / Eli Lilly
Enrollment closed, Combination therapy, Monotherapy, Metastases: A Study of LY3127804 With Ramucirumab in Participants With Advanced Solid Tumors (clinicaltrials.gov) - Oct 4, 2017
P1, N=105, Active, not recruiting, Sponsor: Eli Lilly and Company
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- || Cyramza (ramucirumab) / Eli Lilly, zansecimab (LY3127804) / Eli Lilly
Trial primary completion date, Combination therapy, Monotherapy, Metastases: A Study of LY3127804 With Ramucirumab in Participants With Advanced Solid Tumors (clinicaltrials.gov) - Aug 7, 2017
P1, N=105, Recruiting, Sponsor: Eli Lilly and Company
Recruiting --> Active, not recruiting Trial primary completion date: Dec 2017 --> Mar 2018
- || Cyramza (ramucirumab) / Eli Lilly, zansecimab (LY3127804) / Eli Lilly
Trial primary completion date, Combination therapy, Monotherapy, Metastases: A Study of LY3127804 With Ramucirumab in Participants With Advanced Solid Tumors (clinicaltrials.gov) - Nov 22, 2016
P1, N=105, Recruiting, Sponsor: Eli Lilly and Company
Trial primary completion date: Dec 2017 --> Mar 2018 Trial primary completion date: Sep 2017 --> Dec 2017
- || Cyramza (ramucirumab) / Eli Lilly, zansecimab (LY3127804) / Eli Lilly
Trial primary completion date, Combination therapy, Monotherapy, Metastases: A Study of LY3127804 With Ramucirumab in Participants With Advanced Solid Tumors (clinicaltrials.gov) - May 23, 2016
P1, N=105, Recruiting, Sponsor: Eli Lilly and Company
Trial primary completion date: Sep 2017 --> Dec 2017 Trial primary completion date: Jan 2018 --> Sep 2017
- ||| Cyramza (ramucirumab) / Eli Lilly, zansecimab (LY3127804) / Eli Lilly
Enrollment open, Combination therapy, Monotherapy, Metastases: A Study of LY3127804 With Ramucirumab in Participants With Advanced Solid Tumors (clinicaltrials.gov) - Dec 3, 2015
P1, N=105, Recruiting, Sponsor: Eli Lilly and Company
Trial primary completion date: Jan 2018 --> Sep 2017 Not yet recruiting --> Recruiting
- ||| Cyramza (ramucirumab) / Eli Lilly, zansecimab (LY3127804) / Eli Lilly
New P1 trial, Combination therapy, Monotherapy, Metastases: A Study of LY3127804 With Ramucirumab in Participants With Advanced Solid Tumors (clinicaltrials.gov) - Nov 5, 2015
P1, N=105, Not yet recruiting, Sponsor: Eli Lilly and Company